Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Friday. The firm issued a hold rating on the stock.

A number of other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Ekso Bionics in a report on Tuesday, July 30th. Lake Street Capital started coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They issued a “buy” rating and a $2.50 target price for the company.

Ekso Bionics Price Performance

Shares of EKSO opened at $1.05 on Friday. Ekso Bionics has a 12-month low of $0.75 and a 12-month high of $3.13. The business’s fifty day moving average is $1.09 and its 200 day moving average is $1.17. The company has a quick ratio of 1.77, a current ratio of 2.42 and a debt-to-equity ratio of 0.36. The stock has a market cap of $19.08 million, a P/E ratio of -1.08 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The firm had revenue of $4.95 million during the quarter, compared to the consensus estimate of $5.34 million. During the same quarter in the prior year, the business earned ($0.31) earnings per share. Sell-side analysts anticipate that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.